Clinical Trials Logo

Philadelphia Chromosome Positive clinical trials

View clinical trials related to Philadelphia Chromosome Positive.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01043874 Completed - Clinical trials for Philadelphia Chromosome Positive

Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response

MACS0911
Start date: December 2009
Phase: Phase 4
Study type: Interventional

To evaluate the major molecular response (MMR) rate at 12 months of nilotinib treatment on study in patients with Philadelphia Chromosome Positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) who have a suboptimal molecular response to imatinib at 18 months or later.

NCT ID: NCT00390793 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Start date: September 28, 2006
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well combination chemotherapy and dasatinib works in treating participants with Philadelphia-positive or B-cell receptor-ABL positive acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy in combination with dasatinib may work better in treating participants with Philadelphia-positive or BCR-ABL positive acute lymphoblastic leukemia.